Protara Therapeutics Announces Results From THRIVE-1, A Study Evaluating The Prevalence Of Choline Deficiency And Liver Injury In Patients Dependent On Parenteral Support; Expects To Dose First Patient In Pivotal PK Trial For IV Choline Chloride In Q1 2025
Portfolio Pulse from Benzinga Newsdesk
Protara Therapeutics announced results from the THRIVE-1 study, highlighting a high prevalence of choline deficiency and liver injury in patients dependent on parenteral support. The company plans to start a pivotal trial for IV Choline Chloride in Q1 2025.
September 09, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protara Therapeutics' THRIVE-1 study shows significant choline deficiency in patients on parenteral support, with plans to start a pivotal trial for IV Choline Chloride in Q1 2025. This could address a major unmet medical need.
The study results indicate a significant unmet medical need that Protara's IV Choline Chloride could address. The announcement of a pivotal trial in Q1 2025 suggests progress in their development pipeline, potentially boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100